PRELUDE THERAPEUTICS INC's ticker is PRLD and the CUSIP is 74065P101. A total of 56 filers reported holding PRELUDE THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 2.40 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,856,127 | -40.7% | 5,131,433 | -13.6% | 0.00% | -50.0% |
| Q2 2023 | $26,730,990 | -48.4% | 5,940,220 | -34.7% | 0.00% | 0.0% |
| Q1 2023 | $51,832,128 | +87.0% | 9,093,356 | +98.1% | 0.00% | -33.3% |
| Q4 2022 | $27,721,135 | -9.6% | 4,589,592 | -1.1% | 0.00% | 0.0% |
| Q3 2022 | $30,660,000 | +36.5% | 4,638,547 | +7.8% | 0.00% | +50.0% |
| Q2 2022 | $22,461,000 | -39.4% | 4,302,969 | -19.9% | 0.00% | -33.3% |
| Q1 2022 | $37,065,000 | -49.9% | 5,371,907 | -9.5% | 0.00% | -40.0% |
| Q4 2021 | $73,939,000 | -66.5% | 5,938,933 | -15.8% | 0.01% | -70.6% |
| Q3 2021 | $220,489,000 | +17.5% | 7,055,666 | +7.7% | 0.02% | +13.3% |
| Q2 2021 | $187,598,000 | -30.8% | 6,552,499 | +4.8% | 0.02% | -34.8% |
| Q1 2021 | $270,904,000 | -8.6% | 6,252,107 | +48.5% | 0.02% | -11.5% |
| Q4 2020 | $296,295,000 | +228.8% | 4,209,963 | +34.6% | 0.03% | +188.9% |
| Q3 2020 | $90,109,000 | – | 3,128,384 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 10,039,691 | $287,436,000 | 2.91% |
| Baker Brothers Advisors | 10,123,824 | $289,845,000 | 1.27% |
| Logos Global Management LP | 400,000 | $11,452,000 | 0.96% |
| Rock Springs Capital Management LP | 382,359 | $10,947,000 | 0.22% |
| HHLR ADVISORS, LTD. | 583,333 | $16,701,000 | 0.17% |
| Virtus ETF Advisers LLC | 6,622 | $190,000 | 0.08% |
| Jump Financial, LLC | 13,700 | $392,000 | 0.04% |
| ARS Investment Partners, LLC | 7,400 | $212,000 | 0.02% |
| FEDERATED HERMES, INC. | 336,100 | $9,623,000 | 0.02% |
| UBS ASSET MANAGEMENT AMERICAS LLC | 1,287,735 | $36,867,853,000 | 0.02% |